UBS Group’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-41,042
| Closed | -$164K | – | 10592 |
|
|
2025
Q2 | $164K | Sell |
41,042
-11,936
| -23% | -$29.6K | ﹤0.01% | 6853 |
|
|
2025
Q1 | $48.2K | Buy |
52,978
+16,803
| +46% | +$23.3K | ﹤0.01% | 7627 |
|
|
2024
Q4 | $100K | Buy |
36,175
+10,411
| +40% | +$39.6K | ﹤0.01% | 6873 |
|
|
2024
Q3 | $135K | Buy |
25,764
+9,991
| +63% | +$51.9K | ﹤0.01% | 6150 |
|
|
2024
Q2 | $70.3K | Sell |
15,773
-32,187
| -67% | -$156K | ﹤0.01% | 6423 |
|
|
2024
Q1 | $367K | Buy |
47,960
+1,753
| +4% | +$9.62K | ﹤0.01% | 5431 |
|
|
2023
Q4 | $197K | Buy |
46,207
+27,290
| +144% | +$97K | ﹤0.01% | 5788 |
|
|
2023
Q3 | $79.5K | Sell |
18,917
-2,660
| -12% | -$13.5K | ﹤0.01% | 5985 |
|
|
2023
Q2 | $120K | Buy |
+21,577
| New | +$128K | ﹤0.01% | 5858 |
|
|
2023
Q1 | – | Sell |
-2,834
| Closed | -$2.98K | – | 9949 |
|
|
2022
Q4 | $2.98K | Buy |
+2,834
| New | +$4.95K | ﹤0.01% | 9589 |
|
|
2022
Q3 | – | Sell |
-115
| Closed | -$1K | – | 10615 |
|
|
2022
Q2 | $1K | Sell |
115
-6,198
| -98% | -$27K | ﹤0.01% | 9887 |
|
|
2022
Q1 | $26K | Sell |
6,313
-915
| -13% | -$5.39K | ﹤0.01% | 7143 |
|
|
2021
Q4 | $49K | Buy |
+7,228
| New | +$62.4K | ﹤0.01% | 6909 |
|
|
2021
Q3 | – | Sell |
-48
| Closed | -$1K | – | 9792 |
|
|
2021
Q2 | $1K | Sell |
48
-954
| -95% | -$16.6K | ﹤0.01% | 9154 |
|
|
2021
Q1 | $20K | Buy |
+1,002
| New | +$22.1K | ﹤0.01% | 7383 |
|
|
2020
Q4 | – | Sell |
-536
| Closed | -$14K | – | 8555 |
|
|
2020
Q3 | $14K | Buy |
+536
| New | +$13.3K | ﹤0.01% | 6584 |
|
UBS Group's INZY Position: Q3 2025 in Review
UBS Group sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 41,042 shares — an estimated $164K sold.
UBS Group first reported a position in INZY in Q3 2020 and held it in 16 quarters. The position peaked at $367K in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- UBS Group reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 41,042 Inozyme Pharma shares in Q3 2025, an estimated $164K.
- UBS Group first reported a position in Inozyme Pharma in Q3 2020 and held it in 16 quarters.
- UBS Group's Inozyme Pharma position peaked at $367K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.